SW620 Xenograft Model Service for Colon Cancer

SW620 Xenograft Model Service for Colon Cancer provides a validated preclinical platform for evaluating therapeutic efficacy against metastatic colorectal cancer. Alfa Cytology offers comprehensive SW620 xenograft model services, encompassing model establishment, tumor monitoring, and endpoint analysis, to accelerate your oncology drug discovery and development pipeline with reliable, reproducible data.

Overview of SW620 Xenograft Model for Colon Cancer

The SW620 xenograft model is a widely utilized preclinical tool derived from the SW620 human colorectal adenocarcinoma cell line, which was originally isolated from a lymph node metastasis of a 51-year-old male patient. This model faithfully recapitulates key histopathological and molecular features of metastatic colorectal cancer, including moderate differentiation, epithelial morphology, and relevant oncogenic signaling pathways. Researchers employ the SW620 xenograft to assess tumor growth kinetics, metastatic potential, and therapeutic responses, making it particularly valuable for studying advanced-stage disease and anti-metastatic interventions.

In preclinical oncology research, SW620 xenografts serve as a robust platform for evaluating cytotoxic agents, targeted therapies, and combination regimens. The model exhibits consistent engraftment rates in immunocompromised mouse strains and demonstrates predictable tumor growth curves, enabling statistically powered study designs. Its utility extends to biomarker discovery, pharmacokinetic-pharmacodynamic correlations, and the investigation of drug resistance mechanisms in metastatic colorectal cancer settings.

Figure 1. Cell viability in SW480 and SW620 following incubation with increasing concentrations of ropivacain are presented. (Siekmann, W, et al., 2019)

Cell Line Information: SW620

The SW620 cell line was established in 1973 from a lymph node metastasis of a patient with colorectal adenocarcinoma. It represents a well-characterized model of metastatic colorectal cancer with documented molecular alterations and growth properties. The following table summarizes essential characteristics of the SW620 cell line for preclinical research applications.

Our Services

Alfa Cytology provides end-to-end SW620 xenograft model services tailored to your preclinical research objectives. Our integrated platform covers model establishment, in-life tumor monitoring via caliper or imaging modalities, blood and tissue sampling, comprehensive histopathological analysis, and pharmacodynamic endpoint evaluation. With stringent quality control, documented standard operating procedures, and dedicated project management, we ensure reproducible, high-quality data to support your IND-enabling studies and publication requirements.

Workflow of SW620 Xenograft Model Construction

The construction of SW620 xenograft models follows a standardized, multi-step workflow designed to ensure consistent tumor engraftment, reliable growth kinetics, and reproducible therapeutic outcomes. Each phase is executed under controlled conditions with rigorous quality assurance.

1. Cell Preparation and Quality Control. SW620 cells are expanded under optimal culture conditions, authenticated via STR profiling, and tested for mycoplasma contamination. Only low-passage cells exhibiting robust viability (>95%) and exponential growth are selected for implantation.
2. Animal Preparation and Acclimation. Immunocompromised mice (e.g., NOD-SCID or nude mice) are acclimated for 5-7 days under controlled environmental conditions. Baseline body weights and health assessments are recorded prior to tumor cell inoculation.
3. Tumor Cell Inoculation. SW620 cells are harvested, washed, and resuspended in a 1:1 mixture of serum-free medium and Matrigel at a concentration of 5 x 10^6 to 1 x 10^7 cells per 100-200 microL. The cell suspension is injected subcutaneously into the flank or orthotopically into the cecal wall, depending on study design.
4. Tumor Establishment and Monitoring. Tumor growth is monitored twice weekly using digital calipers. Tumor volume is calculated using the modified ellipsoid formula (length x width^2 x 0.5). Mice are randomized into treatment groups once tumors reach 100-200 mm^3.
5. Treatment Administration and In-Life Monitoring. Test compounds are administered via the specified route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weights, tumor dimensions, and clinical signs are recorded throughout the treatment period.
6. Endpoint Analysis and Sample Collection. At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), molecular analysis (qPCR, Western blot), and pharmacokinetic sampling. Blood is collected for hematology and serum chemistry assessments.

Figure 2: Schematic workflow illustrating the derivation and construction of the SW620 Xenograft Model at Alfa Cytology.

Case Study-SW620 Xenograft Model Development

In a representative preclinical study, the SW620 xenograft model was utilized to evaluate the efficacy of a novel targeted therapeutic agent against metastatic colorectal cancer. Following subcutaneous implantation in immunocompromised mice, tumors were established with consistent latency and exhibited robust growth kinetics suitable for randomized treatment assignment. The investigational compound demonstrated dose-dependent tumor growth inhibition, with significant reductions in tumor volume and weight compared to vehicle-treated controls. Pharmacodynamic analysis revealed modulation of relevant signaling pathways in excised tumor tissue, supporting the mechanism of action. These findings illustrate the utility of the SW620 xenograft platform for generating translational data to guide clinical development strategies.

Why Choose Alfa Cytology?

Alfa Cytology delivers reliable, scientifically rigorous SW620 xenograft model services designed to meet the demands of modern preclinical oncology research. Our commitment to quality, transparency, and client collaboration ensures that every study generates actionable data.

• Validated SW620 xenograft models with documented engraftment rates and growth kinetics.
• Comprehensive in-life monitoring including tumor caliper measurements, body weight tracking, and clinical observation.
• Customizable study designs accommodating subcutaneous, orthotopic, and metastatic model configurations.
• Integrated endpoint analysis encompassing histopathology, immunohistochemistry, biomarker quantification, and pharmacokinetic assessment.
• Dedicated project management with transparent communication, timely reporting, and regulatory-compliant documentation.
• Cost-effective pricing structures without compromising scientific rigor or animal welfare standards.

Contact Us

Ready to advance your colorectal cancer research with our SW620 xenograft model services? Contact us today to discuss your study requirements, receive a customized proposal, and leverage Alfa Cytology's expertise in preclinical oncology model development. Our scientific team is prepared to support your drug discovery pipeline from initial study design through final data delivery---reach out to us and let's collaborate to accelerate your path to clinical success.

For research use only. Not intended for any clinical use.